Lotus Pharmaceuticals Stock Cash Flow From Operations
| LTUS Stock | USD 0.0008 0 75.76% |
Lotus Pharmaceuticals fundamentals help investors to digest information that contributes to Lotus Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Lotus Pink Sheet. The fundamental analysis module provides a way to measure Lotus Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lotus Pharmaceuticals pink sheet.
Lotus |
Lotus Pharmaceuticals Company Cash Flow From Operations Analysis
Lotus Pharmaceuticals' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Lotus Pharmaceuticals Cash Flow From Operations | 26.78 M |
Most of Lotus Pharmaceuticals' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lotus Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Lotus Pharmaceuticals has 26.78 M in Cash Flow From Operations. This is 98.91% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The cash flow from operations for all United States stocks is 97.24% higher than that of the company.
Lotus Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lotus Pharmaceuticals' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Lotus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Lotus Pharmaceuticals by comparing valuation metrics of similar companies.Lotus Pharmaceuticals is currently under evaluation in cash flow from operations category among its peers.
Lotus Fundamentals
| Return On Equity | 0.0182 | |||
| Return On Asset | 0.0456 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 762.17 K | |||
| Shares Outstanding | 27.82 M | |||
| Price To Earning | 0.18 X | |||
| Price To Book | 0.01 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 72.7 M | |||
| Gross Profit | 39.78 M | |||
| EBITDA | 10.31 M | |||
| Net Income | 14.42 M | |||
| Cash And Equivalents | 158.91 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 5.24 M | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 0.53 X | |||
| Book Value Per Share | 3.58 X | |||
| Cash Flow From Operations | 26.78 M | |||
| Earnings Per Share | 0.06 X | |||
| Number Of Employees | 233 | |||
| Beta | 0.51 | |||
| Market Capitalization | 834.49 K | |||
| Total Asset | 103.18 M | |||
| Retained Earnings | 65 M | |||
| Working Capital | (6 M) | |||
| Current Asset | 8 M | |||
| Current Liabilities | 14 M | |||
| Net Asset | 103.18 M |
About Lotus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lotus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lotus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lotus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lotus Pink Sheet Analysis
When running Lotus Pharmaceuticals' price analysis, check to measure Lotus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lotus Pharmaceuticals is operating at the current time. Most of Lotus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lotus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lotus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lotus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.